| Abstract [eng] |
Although local PCa treatment is quite effective and aggressive disease develops for a minority of patients, such PCa cases are associated with worse prognosis and shorter survival; also there is a lack of reliable biomarkers for the evaluation of response to treatment. Blood- and urine-circulating RNA can be used as lowly-invasive biomarkers for diagnostic and prognostic purposes in PCa. We found that miR-148a, -365, -375, and -429 are PCa-specific and have significant associations with clinical-pathological parameters of PCa. Also we demonstrated that the combination of urinary miR-148a and miR-375 is a sensitive molecular tool for noninvasive diagnosis of PCa, while the combination of miR-19b and miR-19a/b specifically predicts biochemical recurrence. Castration resistant prostate cancer (CRPC) remains incurable. Due to the heterogeneous nature of CRPC, approximately 30% of patients are already resistant to these new drugs. In patients treated with abiraterone acetate (AA), urinary miR-148 predicts progression-free survival, while the combination of miR-148a and miR-375 – overall survival. One of the resistance mechanisms could be AR splicing variants (AR-Vs) which lack a ligand binding domain and are constitutively active. We demonstrated that higher level of AR-FL and -V1 transcripts in AA-treated CRPC patients’ blood predicts progression-free survival and overall survival. |
